Mazdutide vs Tirzepatide
Extensively Studied vs FDA Approved
avoid Researched · 95% Both target GLP-1 receptor; additive effects on GI symptoms and hypoglycemia risk.
Molecular Data
Mazdutide Tirzepatide
Weight 4,563.1 Da 4,813.55 Da
Half-life 6-8 days ~5 days (120 hours)
Chain 33 amino acids 39 amino acids
Type Oxyntomodulin analog with fatty acid conjugation Dual GLP-1/GIP agonist
Key Benefits
Mazdutide
01 Up to 20% body weight loss
02 Superior glycemic control versus semaglutide
03 Increased energy expenditure via glucagon receptor activation
04 Improved cardiometabolic markers (BP, lipids, liver fat)
05 Once-weekly injection convenience
Tirzepatide
01 Dramatic weight loss (15-22% body weight)
02 Superior diabetes control
03 Reduced cardiovascular risk (26% reduction in MACE)
04 Improved insulin sensitivity
05 Appetite suppression
06 Preserved muscle mass with exercise
Dosing Protocols
Mazdutide
Start 1.5-3mg weekly, titrate up to 6-9mg based on response / Once weekly injection
Weight loss initiation (3mg target) 1.5mg → 3mg Once weekly
Weight loss progression (4.5mg target) 1.5mg → 3mg → 4.5mg Once weekly
Weight loss optimization (6mg target) 2mg → 4mg → 6mg Once weekly
Maximum weight loss (9mg target) 3mg → 6mg → 9mg Once weekly
T2D management (mild-moderate) 3-4.5mg weekly Once weekly
Tirzepatide
2.5mg starting, titrate up to 5-15mg weekly / Once weekly (same day each week)
Weight loss initiation 2.5mg Once weekly x 4 weeks
Weight loss progression 5mg Once weekly
Weight loss optimization 7.5-10mg Once weekly
Maximum weight loss 12.5-15mg Once weekly
Diabetes management (mild) 5-7.5mg Once weekly
Diabetes management (severe) 10-15mg Once weekly
Side Effects
Mazdutide
Nausea (mild-moderate, typically improves over time)
Diarrhea
Vomiting
Increased heart rate (5-17 bpm observed)
Tirzepatide
Nausea (mild to moderate, first 2-4 weeks)
Appetite reduction
Possible fatigue during adaptation
Diarrhea or constipation
Reduced food cravings
Contraindications
Personal or family history of medullary thyroid carcinoma
MEN2 syndrome history (class warning for GLP-1 agonists)
Pregnancy or breastfeeding (insufficient safety data)
Personal or family history of medullary thyroid carcinoma
Multiple Endocrine Neoplasia syndrome type 2 (MEN2)
Pregnancy or breastfeeding
History of pancreatitis
Research Evidence
Mazdutide Tirzepatide
Status Extensively Studied FDA Approved
References 4 studies 8 studies
Latest — 2025-12
FDA Approved No Yes
This comparison is for educational and research purposes only. Consult a healthcare professional before use.